Loading...
•
Dec 31, 2025
Zimmer Biomet Q4 2025 Earnings Report
Zimmer Biomet reported strong revenue growth and increased adjusted diluted EPS for the fourth quarter of 2025.
Key Takeaways
Zimmer Biomet announced robust financial results for the fourth quarter and full-year 2025, with net sales increasing by 10.9% on a reported basis to $2.244 billion. Adjusted diluted earnings per share rose by 4.8% to $2.42, reflecting strong operational performance and strategic execution.
Fourth quarter net sales increased by 10.9% on a reported basis, reaching $2.244 billion.
Adjusted diluted earnings per share for the fourth quarter increased by 4.8% to $2.42.
The company completed $250 million of share repurchases during the fourth quarter of fiscal 2025.
Zimmer Biomet received U.S. FDA clearance for ROSA® Knee with OptimiZe™, enhancing its robotic knee system.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Zimmer Biomet projects full-year 2026 reported revenue change between 2.5% and 4.5%, with adjusted diluted EPS expected to be in the range of $8.30 to $8.45.
Positive Outlook
- Projected 2026 reported revenue change of 2.5% - 4.5%.
- Projected 2026 constant currency revenue change of 2.0% - 4.0%.
- Projected 2026 organic constant currency revenue change of 1.0% - 3.0%.
- Projected 2026 adjusted diluted EPS of $8.30 - $8.45.
- The company anticipates a positive foreign currency exchange impact of +0.50% on revenue.
Challenges Ahead
- The projected impact of the Paragon 28 acquisition through its one-year anniversary is excluded from organic constant currency revenue change, estimated at approximately 100bps.
- Forward-looking non-GAAP financial measures are not available with unreasonable efforts for reconciliation to GAAP.
- The timing of certain transactions is difficult to predict, and management's plans may change.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...